• First-tier patent for innovative cancer research granted
• Future-proofs development pipeline
• Growing US$36 billion immuno-oncology market

Noxopharm Limited (ASX:NOX), a clinical-stage biotech company, has announced that it has been granted its first patent for the Sofra technology platform by the United States Patent and Trademark Office. The patent relates to how Noxopharm's innovative immune-modulatory oligonucleotides could harness the immune system for the treatment of certain types of cancer. This is a 'first-tier' composition of matter patent, meaning that it protects the structure of Noxopharm's assets for the development of novel pharmaceutical compounds. The patent is part of a wider suite of patent applications relating to the Sofra platform that have been filed by the company working in close collaboration with Hudson Institute of Medical Research. While still in its early days, this cancer research project at a conceptual level indicates that the Sofra platform has versatile applications beyond mitigating inflammation in autoimmune and other chronic diseases, and could also be used to weaponise the immune system when faced with unchecked cancerous growth in the body. The global immuno-oncology market is already sizeable at around US$36 billion, and is expected to grow by 16% a year to around US$88 billion by 2030 as the innovation pipeline continues to produce results. The granting of this first US patent is a major milestone for the Sofra platform, and Noxopharm will continue to develop its cancer-related potential in the months ahead along with its research focusing on reducing inflammation in various diseases like lupus and rheumatoid arthritis.

The granting of the first US patent for the Sofra technology platform is a major milestone for Noxopharm, and the company will continue to develop the platform's cancer-related potential in the months ahead along with its research focusing on reducing inflammation in various diseases.